PREVENTION OF ATROPHIC AGE RELATED MACULAR DEGENERATION

摘要

The present invention provides a biocompatible, sustained release drug delivery system for use in a low dose method for treating dry age-related macular degeneration (AMD), the drug delivery system comprising between about 5 µg and about 20 µg of bevacizumab and a polymeric hyaluronic acid vehicle associated with the bevacizumab, wherein the method comprises the step of injecting the drug delivery system into the vitreous cavity of an eye of a patient with dry AMD, and wherein the drug delivery system releases between about 14 ng and about 120 ng of bevacizumab over a 24 hour period for between about 3 months and about 6 months.